Lund University is celebrating 350 years. Read more on lunduniversity.lu.se

Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.

Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice.

Author:
  • Karin Stenkula
  • Maria Lindahl
  • Jitka Petrlova
  • Jonathan Dalla-Riva
  • Olga Göransson
  • Sam Cushman
  • Ewa Krupinska
  • Helena Jones
  • Jens Lagerstedt
Publishing year: 2014
Language: English
Pages: 797-800
Publication/Series: Diabetologia
Volume: 57
Issue: 4
Document type: Journal article
Publisher: Springer Verlag

Abstract english

Apolipoprotein A-I (apoA-I), the main protein constituent of HDL, has a central role in the reverse cholesterol-transport pathway, which together with the anti-inflammatory properties of apoA-I/HDL provide cardioprotection. Recent findings of direct stimulation of glucose uptake in muscle by apoA-I/HDL suggest that altered apoA-I and HDL functionality may be a contributing factor to the development of diabetes. We have studied the in vivo effects of short treatments with human apoA-I in a high-fat diet fed mouse model. In addition to native apoA-I, we investigated the effects of the cardioprotective Milano variant (Arg173Cys).

Keywords

  • Endocrinology and Diabetes

Other

Published
  • Medical Protein Science
  • Protein Phosphorylation
  • Diabetes and Endocrinology
  • Molecular Endocrinology
  • ISSN: 1432-0428
Maria Lindahl
E-mail: maria.lindahl [at] med.lu.se

Research engineer

Glucose Transport and Protein Trafficking

+46 46 222 08 78

BMC C1118b

66

Lund University Diabetes Centre, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00